- Home
- HCAT
HCAT
Health Catalyst Inc
as of 03-19-2026 3:59pm EST
$1.21
+$0.05
+4.31%
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SOUTH JORDAN |
| Market Cap: | 121.7M | IPO Year: | 2019 |
| Target Price: | $2.53 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.55 | EPS Growth: | -121.74 |
| 52 Week Low/High: | $1.04 - $5.06 | Next Earning Date: | 03-12-2026 |
| Revenue: | $311,136,000 | Revenue Growth: | 1.48% |
| Revenue Growth (this year): | -1.12% | Revenue Growth (next year): | 2.92% |
| P/E Ratio: | -0.45 | Index: | N/A |
| Free Cash Flow: | -237000.0 | FCF Growth: | N/A |
AI-Powered HCAT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 72.67%
72.67%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLMar 12, 2026 · 100% conf.
AI Prediction SELL
1D
-11.72%
$2.17
Act: -2.44%
5D
-12.71%
$2.15
Act: -10.16%
20D
-11.17%
$2.19
Act: -16.26%
Price: $2.46 Prob +5D: 0% AUC: 1.000
0001636422-26-000031
hcat-20260312FALSE000163642200016364222026-03-122026-03-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026
HEALTH CATALYST, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3899345-3337483 (State or other jurisdiction of incorporation) (Commission File Number)(IRS Employer Identification No.)
10897 South River Front Parkway #300 South Jordan, UT 84095 (Address of principal executive offices, including zip code)
(801) 708-6800 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of exchange on which registered Common Stock, par value $0.001 per shareHCATThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ((§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On March 12, 2026, Health Catalyst, Inc. (the Company) issued a press release relating to its financial results for the quarter and year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The foregoing information (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the Securities Act), except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. Exhibit No.Description 99.1* Health Catalyst, Inc. press release for quarterly and annual financial results, dated March 12, 2026
104Cover page Interactive Data File (embedded within the Inline XBRL document)
* Furnished herewith.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTH CATALYST, INC.
Date: March 12, 2026 By:/s/ Jason Alger Jason Alger
Chief Financial Officer
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
AI Prediction SELL
1D
-11.72%
$2.17
Act: -2.44%
5D
-12.71%
$2.15
Act: -10.16%
20D
-11.17%
$2.19
Act: -16.26%
Price: $2.46 Prob +5D: 0% AUC: 1.000
0001636422-26-000006
hcat-20260112FALSE000163642200016364222026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026
HEALTH CATALYST, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3899345-3337483 (State or other jurisdiction of incorporation) (Commission File Number)(IRS Employer Identification No.)
10897 South River Front Parkway #300 South Jordan, UT 84095 (Address of principal executive offices, including zip code)
(801) 708-6800 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of exchange on which registered Common Stock, par value $0.001 per shareHCATThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ((§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On January 12, 2026, Health Catalyst, Inc. (the “Company”) published certain preliminary unaudited estimated 2025 financial and operational results and forward-looking commentary (“Excerpt”). These preliminary unaudited estimated results are subject to change upon completion of the Company’s accounting and annual audit procedures and are therefore subject to adjustment. Additional information and disclosures would be required for a more complete understanding of the Company’s results of operations and financial condition as of December 31, 2025. A copy of the Excerpt is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The foregoing information (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
Exhibit No.Description 99.1 Excerpt
104Cover page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTH CATALYST, INC.
Date: January 12, 2026By:/s/ Jason Alger Jason Alger
Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 10, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 10, 2025
0001636422-25-000143
hcat-20251110FALSE000163642200016364222025-11-102025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025
HEALTH CATALYST, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3899345-3337483 (State or other jurisdiction of incorporation) (Commission File Number)(IRS Employer Identification No.)
10897 South River Front Parkway #300 South Jordan, UT 84095 (Address of principal executive offices, including zip code)
(801) 708-6800 (Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of exchange on which registered Common Stock, par value $0.001 per shareHCATThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ((§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 10, 2025, Health Catalyst, Inc. (the “Company”) issued a press release relating to its financial results for the quarter ended September 30, 2025. A copy of the press release and the Q3 2025 earnings release summary are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are each incorporated herein by reference.
The foregoing information (including Exhibits 99.1 and 99.2 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. Exhibit No.Description 99.1* Health Catalyst, Inc. press release for quarterly financial results, dated November 10, 2025
99.2* Q3 2025 Earnings Release Summary
104Cover page Interactive Data File (embedded within the Inline XBRL document)
* Furnished herewith.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTH CATALYST, INC.
Date: November 10, 2025 By:/s/ Jason Alger Jason Alger
Chief Financial Officer
Latest Health Catalyst Inc News
HCAT Breaking Stock News: Dive into HCAT Ticker-Specific Updates for Smart Investing
Compare HCAT vs Leading Stocks
See how HCAT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HCAT Health Catalyst Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.